Gene and Cell Therapy Institute

With the Gene and Cell Therapy Institute, gene and cell therapy research at Mass General Brigham is rapidly advancing, pushing the technological and clinical boundaries of this new frontier.

At Mass General Brigham, we are at the forefront of gene and cell therapy, pushing the boundaries of technology and clinical applications, advancing medical technologies that are revolutionizing patient care.

About the Gene and Cell Therapy Institute

The Gene and Cell Therapy Institute (GCTI) at Mass General Brigham is committed to finding targeted and transformative treatments that have the potential to cure diseases or halt their progression. The GCTI is committed to finding targeted and transformative treatments that have the potential to cure diseases or halt their progression. Our multidisciplinary approach unites more than 500 researchers and clinicians dedicated to advancing gene and cell therapy. We leverage expertise from across the entire Mass General Brigham ecosystem of medical innovation and foster an environment of shared knowledge. Led by renowned cardiac gene therapy pioneer Roger Hajjar, MD, the GCTI accelerates groundbreaking research, conducts clinical trials, and facilitates the development of FDA-approved treatments.

The GCTI is committed to expediting the pace of discovery and development by bridging the gap between academic research and practiceindustry development. The close relationships between industry, physicians, researchers, and patients enables translation to clinical applications. The GCTI also offers expertise in manufacturing, regulatory, clinical trials, and core laboratory services.

The GCTI's annual research symposium is an exploration of the dynamic research landscape within the Mass General Brigham community, uniting trailblazers who are driving advancements in gene therapies, cell therapies, and gene editing techniques to combat human diseases.

Lab Cores

The Gene and Cell Therapy Institute at Mass General Brigham offers expertise in core laboratory services, helping to expedite the pace of discovery and development of new gene and cell therapies.

Discover our expertise

Leaders in Gene and Cell Therapy Research

The Gene and Cell Therapy Institute's leadership actively fosters and establishes both internal and external connections to drive forward the advancement of gene and cell therapy treatments and groundbreaking discoveries.

Roger J. Hajjar, MD

Roger Hajjar, MD, an internationally recognized scientist whose cardiac gene therapy discoveries have spurred clinical trials for heart failure, and whose methodologies for cardiac-directed gene transfer are currently utilized by investigators around the world, is head of the Gene and Cell Therapy Institute at Mass General Brigham.

Meet Dr. Hajjar

News & highlights

Mass General Brigham teams are leading novel approaches in innovation and improved patient care.

Contact us

The future of gene and cell therapy will be built on collaboration and partnerships. If you work at Mass General Brigham and want to learn more on how the GCTI provides support, please reach out to us. Or if you’re from industry seeking potential ways to collaborate, we’d love to hear from you.

Email us